NasdaqGS - Delayed Quote • USD
NovoCure Limited (NVCR)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 6:47 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 7 | 7 |
Avg. Estimate | -0.42 | -0.44 | -1.76 | -1.83 |
Low Estimate | -0.52 | -0.51 | -1.99 | -2.26 |
High Estimate | -0.36 | -0.37 | -1.49 | -1.48 |
Year Ago EPS | -0.5 | -0.54 | -1.95 | -1.76 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 7 | 7 | 7 | 7 |
Avg. Estimate | 131.45M | 133.76M | 538.3M | 580.66M |
Low Estimate | 129.43M | 131.8M | 529M | 567M |
High Estimate | 135M | 136.3M | 546.9M | 596.9M |
Year Ago Sales | 127.28M | -- | 509.34M | 538.3M |
Sales Growth (year/est) | 3.30% | -- | 5.70% | 7.90% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.32 | -0.5 | -0.52 | -0.52 |
EPS Actual | -0.5 | -0.54 | -0.46 | -0.45 |
Difference | -0.18 | -0.04 | 0.06 | 0.07 |
Surprise % | -56.20% | -8.00% | 11.50% | 13.50% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.42 | -0.44 | -1.76 | -1.83 |
7 Days Ago | -0.42 | -0.44 | -1.76 | -1.83 |
30 Days Ago | -0.42 | -0.44 | -1.73 | -1.82 |
60 Days Ago | -0.48 | -0.48 | -1.89 | -2.06 |
90 Days Ago | -0.47 | -0.47 | -1.89 | -2.06 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | 1 | 2 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | NVCR | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 16.00% | -- | -- | 1.60% |
Next Qtr. | 18.50% | -- | -- | 10.50% |
Current Year | 9.70% | -- | -- | 5.20% |
Next Year | -4.00% | -- | -- | 13.30% |
Next 5 Years (per annum) | 60.00% | -- | -- | 11.22% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
Earnings
Upgrades & Downgrades
Reiterates | Piper Sandler: Overweight to Overweight | 4/10/2024 |
Maintains | Wells Fargo: Overweight to Overweight | 4/3/2024 |
Maintains | HC Wainwright & Co.: Neutral to Neutral | 3/27/2024 |
Maintains | JP Morgan: Neutral to Neutral | 3/19/2024 |
Reiterates | HC Wainwright & Co.: Neutral to Neutral | 3/12/2024 |
Maintains | Evercore ISI Group: In-Line to In-Line | 2/23/2024 |
Related Tickers
NARI Inari Medical, Inc.
38.59
-0.13%
MASI Masimo Corporation
134.77
-0.85%
QDEL QuidelOrtho Corporation
39.12
+2.25%
INMD InMode Ltd.
17.41
+0.40%
INGN Inogen, Inc.
6.75
-4.80%
SWAV Shockwave Medical, Inc.
329.00
+0.45%
BFLY Butterfly Network, Inc.
0.7646
-6.76%
PODD Insulet Corporation
166.25
+0.92%
MOTS Motus GI Holdings, Inc.
0.1735
0.00%
CUTR Cutera, Inc.
1.9500
-15.22%